#Netherlands #Rotterdam #SkylineDx #melanoma #Merlin CP-GEP

SkylineDx's Paradigm-Shifting Research on Melanoma Risk Assessment

On April 4, 2025, SkylineDx delivered a pivotal presentation at the World Congress of Melanoma, revealing significant findings that could reshape melanoma risk assessment and management. The study, led by Dr. Teresa Amaral from the University of Tübingen, centered on the Merlin CP-GEP (Clinicopathologic and Gene Expression Profile) test, a diagnostic tool that enhances our understanding of patient risk beyond the traditional methods of delineating melanoma severity.

Understanding Merlin CP-GEP and Its Implications

Melanoma continues to pose a critical public health concern, where accurate risk assessment is paramount for improving treatment strategies and patient outcomes. The conventional approach relies heavily on sentinel lymph node biopsy (SLNB) for staging; however, this method has limitations that can result in missed opportunities for timely intervention in high-risk patients. During the study, 930 patients with stage I/II melanoma were analyzed, out of which the Merlin test effectively classified individuals as either low-risk or high-risk.

The results were compelling: 879 patients (94.5%) were classified into the Low-Risk category, which reported an excellent 5-year and 10-year relapse-free survival (RFS) rates of 96% and 94.5%, respectively. Conversely, the 51 high-risk patients (5.5%) showcased a stark reality: they were nearly 20 times more likely to experience a recurrence, with RFS rates plummeting to 37.5% over the same periods.

Highlights from the Study

• - Identification of High-Risk Patients: Conventional SLNB criteria often underreport relapse risks. The Merlin CP-GEP's incorporation of gene expression data with clinical characteristics provides a comprehensive view, identifying patients overlooked by standard evaluations.
• - Improved Long-Term Outcomes: The findings indicate that the high-risk cohort faces significantly heightened chances of metastasis and mortality, underscoring the necessity for personalized treatment approaches.

Dr. Amaral emphasized, “The results of this study underscore the potential of the Merlin CP-GEP test to redefine risk assessment for melanoma patients. By identifying high-risk individuals who may not have undergone SLNB, we can better tailor treatment decisions, ultimately enhancing patient care.”

The Road Ahead for Clinical Applications

Reflecting on these findings, Dr. Jvalini Dwarkasing, Chief Scientific Officer at SkylineDx, elaborated on the potential benefits of systemic therapy for high-risk patients. “The results highlight the power of CP-GEP in helping clinicians identify high-risk patients, even in the absence of SLNB status. Further research is essential, but these high-risk patients could benefit from treatments aimed at preventing recurrence, akin to current immunotherapy strategies.”

This discovery points toward a more nuanced understanding of melanoma progression and reinforces SkylineDx’s mission to provide advanced molecular diagnostics that enable personalized healthcare solutions.

About the Merlin CP-GEP Test

SkylineDx’s Merlin CP-GEP test distinguishes itself as the only non-invasive GEP model combining clinicopathologic variables with gene expression profiling. This innovative tool provides a binary stratification that allows for clearer treatment pathways based on a patient's metastasis risk. Developed in collaboration with the Mayo Clinic, it has undergone rigorous clinical validation across multiple global studies.

Conclusion

As melanoma rates continue to rise, the need for advanced diagnostic solutions like the Merlin CP-GEP becomes ever more critical. SkylineDx remains steadfast in its commitment to revolutionize melanoma risk assessment and improve patient outcomes through cutting-edge research and technology. For further insights and developments from SkylineDx, visit SkylineDx Website.